Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Wedbush decreased their Q3 2025 EPS estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.14). The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics' FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.53) EPS.
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.10. The company had revenue of $6.27 million during the quarter, compared to the consensus estimate of $0.09 million. Ovid Therapeutics had a negative net margin of 574.44% and a negative return on equity of 58.87%.
A number of other brokerages also recently commented on OVID. Wall Street Zen upgraded shares of Ovid Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. B. Riley restated a "buy" rating and set a $3.00 price objective on shares of Ovid Therapeutics in a research report on Friday, August 8th. HC Wainwright cut their price objective on shares of Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating for the company in a research report on Tuesday, May 27th. Finally, William Blair upgraded shares of Ovid Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $3.10.
Check Out Our Latest Analysis on OVID
Ovid Therapeutics Stock Performance
Ovid Therapeutics stock traded up $0.0730 during trading hours on Monday, reaching $1.03. 1,199,135 shares of the stock were exchanged, compared to its average volume of 1,525,876. The stock has a market cap of $73.24 million, a P/E ratio of -1.94 and a beta of 0.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.72 and a current ratio of 4.72. Ovid Therapeutics has a 52-week low of $0.2425 and a 52-week high of $1.47. The firm's 50 day moving average is $0.52 and its 200 day moving average is $0.44.
Hedge Funds Weigh In On Ovid Therapeutics
Large investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its holdings in Ovid Therapeutics by 699.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 560,830 shares of the company's stock valued at $175,000 after acquiring an additional 490,716 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Ovid Therapeutics by 142.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company's stock valued at $101,000 after acquiring an additional 63,200 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ovid Therapeutics by 50.2% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company's stock valued at $881,000 after acquiring an additional 315,126 shares in the last quarter. XTX Topco Ltd purchased a new position in Ovid Therapeutics during the 1st quarter valued at about $29,000. Finally, Velan Capital Investment Management LP purchased a new position in Ovid Therapeutics during the 4th quarter valued at about $65,000. Hedge funds and other institutional investors own 72.24% of the company's stock.
About Ovid Therapeutics
(
Get Free Report)
Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
Further Reading
Before you consider Ovid Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.
While Ovid Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
